The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

NCT ID: NCT05536102

Last Updated: 2023-03-09

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-05
• Study Completion Date: 2027-09-30

Brief Summary

This is a signle-arm, multi-center, open-lable, phase II study. The objective is to evaluate the effectiveness and safety of tislelizumab + oxaliplatin + capecitabine + PLD in the neoadjuvant treatment of resectable gastric adenocarcinoma.

Detailed Description

This single-arm, multicenter, open-label study plan to enroll patients with resectable stage III gastric adenocarcinoma to recieve tislelizumab + oxaliplatin + capecitabine + PLD regimen for 2 or 4 cycles, radical resection will be performed after neoadjuvant therapy. Radiological evaluation will be performed every 2 cycles to evaluate the resectability of tumor. Survival follow-up will be performed after surgery, until patient's withdrawal of informed consent, loss to follow-up or death, whichever comes first.

Conditions

Gastric Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experiment group

Pegylated Liposomal Doxorubicin + Oxaliplatin + Capecitabine + Tislelizumab; reapt every 21 days.

Group Type: EXPERIMENTAL

PLD

Intervention Type: DRUG

20mg/m2, day 1, q3w

Oxaliplatin

Intervention Type: DRUG

130 mg/m2, day 1, q3w

Capecitabine

Intervention Type: DRUG

1000 mg/m2, days 1-14, q3w

Tislelizumab

Intervention Type: DRUG

200 mg, day 1, q3w

Interventions

PLD

20mg/m2, day 1, q3w

Intervention Type: DRUG

Oxaliplatin

130 mg/m2, day 1, q3w

Intervention Type: DRUG

Capecitabine

1000 mg/m2, days 1-14, q3w

Intervention Type: DRUG

Tislelizumab

200 mg, day 1, q3w

Intervention Type: DRUG

Other Intervention Names

Pegylated Liposomal Doxorubicin; Eloxatin; Xeloda; BGB-A317

Eligibility Criteria

Inclusion Criteria

1. Age: 18~75 years old.

2. Karnofsky Performance Status Score ≥70.

3. Histological or cytological diagnosed as gastric adenocarcinoma, HER2-, PD-1/L1+.

4. Clinical stage stage III (8th edition of the AJCC Cancer Staging Manual).

5. Physical condition and organ function allow for larger abdominal surgery.

6. Subject baseline blood routine and biochemical indicators meet the following standards: hemoglobin ≥90g/L; absolute neutrophil count (ANC) ≥1.5×10^9g/L; platelets counts (PLT) ≥100×10^9/L; alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤2.5 times the upper limit of normal (ULN); serum total bilirubin <1.5 ULN; serum creatinine <1 ULN; serum albumin ≥30g/L.

7. Heart function:

1. Left ventricular ejection fraction (LVEF) ≥50%;

2. 12-ECG indicates no myocardial ischemia;

3. No history of arrhythmia requiring drug intervention before enrollment;

8. No serious concomitant diseases that make the survival time < 5 years.

9. Agree and be able to comply with the protocol during the study period.

10. Provide written informed consent before entering the study.

Exclusion Criteria

1. Received chemotherapy, radiotherapy or immunotherapy for this gastric cancer.

2. Pregnant or breastfeeding women.

3. Women of childbearing age who had a positive pregnancy test at baseline or who did not have a pregnancy test. Menopausal women must have menopause for at least 12 months before they can become pregnant.

4. Men and women who are sexually active (possible to have children) are unwilling to use contraception during the study period.

5. Patients with mass ascites and positive abdominal free cancer cells.

6. With a history of other malignancies in the last 5 years, except for cured non-melanoma skin cancer and cervical carcinoma in situ.

7. With a history of epilepsy, central nervous system disease, or mental disorder may be judged by the investigator that their clinical severity may hinder the signing of informed consent or affect the patient's oral medication compliance.

8. Clinically severe (i.e. active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) grade II or more severe congestive heart failure, or severe arrhythmia requiring medical intervention, or the last 12 There was a history of myocardial infarction within months.

9. Patients deficiency of dihydropyrimidine dehydrogenase (DPD).

10. Peripheral nerve disease ≥ NCI CTC AE grade 2. However, the patients only with deep tendon reflex (DTR) disappears do not need to be excluded.

11. Organ transplantation requires immunosuppressive therapy.

12. Severe uncontrolled repeated infections, or other serious uncontrolled concomitant diseases.

13. Moderate or severe renal damage [creatinine clearance ≤50ml/min (calculated according to Cockroft and Gault equation), or serum creatinine> ULN].

14. Acute or chronic active hepatitis B, hepatitis C infection, hepatitis B virus (HBV) DNA>2000IU/ml or 10^4 copies/ml, hepatitis C virus (HCV) RNA>10^3 copies/ml, hepatitis B surface antigen (HbsAg) is positive at the same time as anti-HCV antibody.

15. Allergic to any research drug ingredients.

16. Participating in other trials within 4 weeks before enrollment.

17. Not suitable to participate in this trial for any reason judged by the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Qi Li

Chief Physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Qi Li

Role: STUDY_CHAIR

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Locations

Shanghai General Hospital

Shanghai, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Qi Li, Prof.

Role: CONTACT

Leeqi2001@hotmail.com

13818207333

Facility Contacts

Jingyi Zhou, Dr.

Role: primary

jingyi_z2020@sjtu.edu.cn

15618122509

Other Identifiers

CSPC-DMS-GC-04

Identifier Type: -

Identifier Source: org_study_id